We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+8.63%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$9.44B
AUM Growth
-$323M
(-3.3%)
Cap. Flow
-$311M
Cap. Flow
% of AUM
-3.3%
Top 10 Holdings %
Top 10 Hldgs %
61.29%
Holding
95
New
24
Increased
17
Reduced
2
Closed
10
Top Buys
| 1 |
SGP
SpyGlass Pharma
SGP
|
+$216M |
| 2 |
Wave Life Sciences
WVE
|
+$114M |
| 3 |
Zai Lab
ZLAB
|
+$106M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$75.5M |
| 5 |
Nuvalent
NUVL
|
+$66.7M |
Top Sells
| 1 |
CDTX
Cidara Therapeutics
CDTX
|
+$743M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$623M |
| 3 |
ACLX
Arcellx
ACLX
|
+$82.6M |
| 4 |
BLTE
Belite Bio
BLTE
|
+$69.2M |
| 5 |
Invivyd
IVVD
|
+$42.3M |
Sector Composition
| 1 | Healthcare | 99.71% |
| 2 | Financials | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$17.4B
| $2.35B | 24.92% |
10,281,496
| – | – |
|
2
Vaxcyte
PCVX
$8.12B
| $667M | 7.07% |
11,474,599
+750,000
| +7% | +$40.7M |
|
3
Rhythm Pharmaceuticals
RYTM
$7.54B
| $580M | 6.14% |
6,666,837
| – | – |
|
4
Tyra Biosciences
TYRA
$1.96B
| $467M | 4.95% |
12,198,625
| – | – |
|
|
SION
5
Sionna Therapeutics
SION
$1.92B
| $397M | 4.21% |
9,905,045
| – | – |
|
6
Edgewise Therapeutics
EWTX
$4.27B
| $328M | 3.48% |
10,428,437
| – | – |
|
7
NewAmsterdam Pharma
NAMS
$3.89B
| $306M | 3.24% |
9,550,191
| – | – |
|
|
8
Nuvalent
NUVL
$9.81B
| $260M | 2.75% |
2,534,145
+654,088
| +35% | +$66.7M |
|
9
Dianthus Therapeutics
DNTH
$5.54B
| $219M | 2.32% |
2,611,733
+1,000,000
| +62% | +$57.9M |
|
10
Mineralys Therapeutics
MLYS
$2.4B
| $208M | 2.21% |
7,692,750
+369,000
| +5% | +$10.8M |
|
|
SGP
11
SpyGlass Pharma
SGP
$668M
| $208M | 2.2% |
+8,021,117
| New | +$216M |
|
|
12
Wave Life Sciences
WVE
$1.18B
| $196M | 2.07% |
26,975,505
+8,772,496
| +48% | +$114M |
|
|
SEPN
13
Septerna Inc
SEPN
$1.56B
| $168M | 1.78% |
6,995,858
| – | – |
|
14
Disc Medicine
IRON
$2.87B
| $157M | 1.66% |
2,450,221
+474,089
| +24% | +$32.9M |
|
15
Janux Therapeutics
JANX
$962M
| $156M | 1.65% |
11,189,693
| – | – |
|
16
BioCryst Pharmaceuticals
BCRX
$2.48B
| $151M | 1.6% |
15,827,186
| – | – |
|
|
BCAX
17
Bicara Therapeutics
BCAX
$1.85B
| $144M | 1.53% |
7,255,993
+300,000
| +4% | +$5.16M |
|
18
Praxis Precision Medicines
PRAX
$9.14B
| $120M | 1.28% |
373,787
| – | – |
|
19
GH Research
GHRS
$1.84B
| $108M | 1.14% |
7,676,697
| – | – |
|
|
20
Zai Lab
ZLAB
$2.18B
| $107M | 1.14% |
+5,707,262
| New | +$106M |
|
21
Taysha Gene Therapies
TSHA
$1.64B
| $105M | 1.12% |
23,555,648
| – | – |
|
22
Vor Biopharma
VOR
$1B
| $96.4M | 1.02% |
5,404,998
| – | – |
|
23
Geron
GERN
$885M
| $95M | 1.01% |
63,771,366
| – | – |
|
24
ARS Pharmaceuticals
SPRY
$756M
| $87.2M | 0.92% |
10,860,977
| – | – |
|
|
25
Sarepta Therapeutics
SRPT
$1.9B
| $84.9M | 0.9% |
+3,902,596
| New | +$75.5M |
|
Similar funds
SCM
AIM
MIF
SIM
NPT
AC
PVI
WPL